CARGO Therapeutics, Inc. Common Stock (CRGX)
CARGO Therapeutics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in San Mateo, DE, US. The stock last traded at $4.47, up 0.00% on the session, giving a market capitalisation of $216.2M. On trailing twelve-month figures it carries a trailing P/E of -1.59, a net margin of 0.0%. Its beta of 0.29 implies it has historically moved less than the broad market.
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
CARGO Therapeutics, Inc. Common Stock is most often compared with the following Healthcare names: